



an Open Access Journal by MDPI

# Inhaled Treatment of Respiratory Infections, 2nd Edition

Guest Editors:

# Dr. Philip Chi Lip Kwok

Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, Pharmacy and Bank Building A15, The University of Sydney, Sydney, NSW 2006, Australia

#### Dr. Michael Y. T. Chow

UCL School of Pharmacy, University College London, London WC1E 6BT, UK

Deadline for manuscript submissions: **31 August 2024** 

#### **Message from the Guest Editors**

Dear Colleagues,

Respiratory infections are conventionally treated with oral or intravenous antimicrobials (antibiotics, antifungals, antivirals). However, these routes of administration are not ideal because the required drugs are systemically delivered rather than being targeted to the respiratory tract. Higher doses may also be needed to achieve sufficiently high drug concentrations in the lungs, which may consequently cause more adverse effects. On the other hand, the drugs can be delivered efficiently into the airways as inhaled aerosols. Lower doses can then be used to attain relatively high local concentrations. There are specific challenges to the development of inhaled formulations, such as optimising their physicochemical stability and aerosol performance. In addition, antimicrobial resistance is an urgent global public health issue. Novel strategies are required to overcome these problems.

This Special Issue, Inhaled Treatment of Respiratory Infections—Volume II, will focus on recent advances in treating respiratory infections with inhaled formulations.

**Special**sue



mdpi.com/si/164125





an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

#### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## **Contact Us**

*Pharmaceutics* Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/pharmaceutics pharmaceutics@mdpi.com X@MDPIpharma